Subscribe
US Food and Drug Administration's Division of Biologic Oncology Products has approved two new biologics license application (BLA) supplements expanding the approval of Genentech's Herceptin (trastuzumab) for the treatment of breast cancer.
Iontophoresis, Sonophoresis, and Microneedles Permit Effective Transdermal Delivery of Biologics
259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512
609-716-7777